

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/101,413
		Filing Date	August 7, 1998
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1643
		Examiner Name	
		Attorney Docket Number	RPMS 102
Sheet	1	of	3

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	US Patent Document Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
mtc		4,844,893	Honsik, et al.	07-04-1989	
mtc		4,690,915	Rosenberg	09-01-1987	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
mtc		DAHL, et al., "Normal Self Proteins as Targets for Tumour Specific Cytotoxic Lymphocytes (CTL)," <i>9th International Congress of Immunology, San Francisco, CA, USA</i> 607 (1995).	
		DAHL, et al., "A synthetic peptide derived from the tumor-associated protein mdm2 can stimulate autoreactive, high avidity cytotoxic T lymphocytes that recognize naturally processed protein," <i>J Immunol</i> 157(1):239-46 (1996).	
		HILL, et al., "Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised," <i>J Exp Med</i> 181(6):2221-8 (1995).	
		HSU, et al., "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells," <i>Nat Med</i> 2(1):52-8 (1996).	
		INOUE, et al., "Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels," <i>Blood</i> 88(6):2267-78 (1996).	
		JEROME, et al., "Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA," <i>J Immunol</i> 151(3):1654-62 (1993).	
		KAWAKAMI, et al., "Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas," <i>J Immunol</i> 148(2):638-43 (1992).	

Examine Signature	M. T. Lunt	Date Considered	1-12-2000
----------------------	------------	--------------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/101,413
		Filing Date	August 7, 1998
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1643
		Examiner Name	
		Attorney Docket Number	RPMS 102
Sheet	2	of	3

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			T ²
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	
MTC		KWAK, et al., "Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor," <i>Lancet</i> 345(8956):1016-20 (1995).	
		LU, et al., "Improved Synthesis of 4-Alkoxybenzyl Alcohol Resin," <i>J. Org. Chem.</i> 46: 3433-3436 (1981).	
		MELIEF, Prospects of T-cell immunotherapy for cancer by peptide vaccination," <i>Semin Hematol</i> 30(3 Suppl 3):32-3 (1993).	
		MENNSEN, et al., "Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias," <i>Leukemia</i> 9(6):1060-7 (1995).	
		MURPHY, et al., "Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen," <i>Prostate</i> 29(6):371-80 (1996).	
		PEOPLES, et al., "Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide," <i>Proc Natl Acad Sci U S A</i> 92(2):432-6 (1995).	
		PLEBANSKI, et al., "Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood," <i>Eur J Immunol</i> 25(6):1783-7 (1995).	
		RODECK, et al., "Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes," <i>Int J Cancer</i> 59(1):78-82 (1994).	
		SHIMAMOTO, et al., "The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia," <i>Blood</i> 86(8):3173-80 (1995).	
		TAMAKI, et al., "Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia," <i>Blood</i> 88(11):4396-8 (1996).	

Examiner's Signature	<i>M.T. Lutz</i>	Date Considered	1-12-2000
----------------------	------------------	-----------------	-----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

